GlassScriptPhysician profile
Danielle Monica Lo
NPI 1164878948
$9,795.69
in general payments reported to CMS, 2019-2025
32 companies · $1,621 in 2025
The $1,621 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $450 · 2021: $1,934 · 2022: $2,235 · 2023: $1,825 · 2024: $1,730 · 2025: $1,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,176.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,395.87 | 2022-2025 | Envista Mx60 Iol, Amvisc, Miebo |
| Alcon Vision LLC | $1,394.26 | 2020-2025 | Rocklatan, Clareon, Acrysof Iq Panoptix Uv Iol |
| Sun Pharmaceutical Industries INC. | $1,267.36 | 2020-2025 | Cequa, Xelpros, Bromsite |
| Abbvie INC. | $1,045.62 | 2022-2025 | |
| Sight Sciences, INC. | $687.87 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Aerie Pharmaceuticals, INC. | $483.30 | 2020-2021 | |
| Amgen INC. | $358.46 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $338.59 | 2022-2023 | Tepezza |
| Allergan, INC. | $336.79 | 2020-2022 | |
| Oyster Point Pharma, INC. | $299.19 | 2022-2025 | Tyrvaya |
| Ivantis, INC | $287.90 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $252.86 | 2021-2023 | Tecnis Iol, Veritas Vision System, Catalys System |
| Dompe US, INC. | $176.82 | 2021-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $163.07 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $152.74 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $140.89 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $138.69 | 2021-2025 | Acthar |
| Tarsus Pharmaceuticals, INC. | $137.36 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $134.99 | 2024-2025 | Vevye, Iheezo |
| Eyevance Pharmaceuticals LLC | $112.15 | 2020-2022 | |
| Beaver-Visitec International, INC. | $97.82 | 2022 | |
| Thea Pharma INC. | $81.29 | 2023-2025 | Iyuzeh |
| Ani Pharmaceuticals, INC. | $69.51 | 2025 | Purified Cortrophin Gel |
| Merz Pharmaceuticals, LLC | $59.02 | 2025 | Xeomin |
| Coopervision INC. | $47.86 | 2022 | |
| Apellis Pharmaceuticals, INC. | $26.31 | 2023 | Syfovre |
| Ocular Therapeutix, INC. | $20.61 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Akorn, INC. | $18.41 | 2020 | |
| Biotissue Holdings INC. | $18.15 | 2022 | |
| Rxsight INC | $18.02 | 2022 | |
| Nova Eye, INC. | $14.51 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.